Replies to post #139891 on Biotech Values

[mcbio]

Do current developments in the HCV space--namely, the results from ABT's combo regimen--make BLRX's in-licensing of the two HCV drugs any less ridiculous than everyone first assumed?

What made it ridiculous in the first place was that they implied they had in-licensed some novel HCV asset when in fact they had just in-licensed another HCV PI, at the pre-clinical stage no less. The current developments don't change my thoughts on that at all.